Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease

NPJ Parkinsons Dis. 2024 Mar 14;10(1):60. doi: 10.1038/s41531-024-00658-6.
No abstract available

Publication types

  • Letter